Center for Breakthrough Medicines Revenue and Competitors
Claim your profile
Estimated Revenue & Valuation
- Center for Breakthrough Medicines's estimated annual revenue is currently $50.4M per year.
- Center for Breakthrough Medicines's estimated revenue per employee is $147,295
- Center for Breakthrough Medicines's total funding is $350M.
Employee Data
- Center for Breakthrough Medicines has 342 Employees.
- Center for Breakthrough Medicines grew their employee count by 139% last year.
Center for Breakthrough Medicines Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $1.6M | 8 | 0% | N/A | N/A |
#2 | $3.4M | 17 | 0% | N/A | N/A |
#3 | $0.5M | 7 | 0% | N/A | N/A |
#4 | $0.8M | 12 | 20% | N/A | N/A |
#5 | $4.3M | 57 | 8% | N/A | N/A |
#6 | N/A | 6 | -14% | N/A | N/A |
#7 | $5.4M | 25 | -11% | N/A | N/A |
#8 | $0.5M | 9 | 125% | N/A | N/A |
#9 | $8.4M | 44 | -2% | N/A | N/A |
#10 | $0.6M | 10 | -23% | N/A | N/A |
What Is Center for Breakthrough Medicines?
$350M
Total Funding
342
Number of Employees
$50.4M
Revenue (est)
139%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Center for Breakthrough Medicines News
2022-04-13 - Achilles joins Center for Breakthrough Medicines site near ...
Josh Sullivan. Associate Editor. Another CDMO is joining the Center for Breakthrough Medicines. London-based Achilles Therapeutics has inked a deal...
2022-04-13 - Center for Breakthrough Medicines to make cell therapies for ...
Center for Breakthrough Medicines' latest deal is with London biotech firm Achilles Therapeutics.
2022-04-06 - The Center for Breakthrough Medicines (CBM) Strikes Multi ...
The Center for Breakthrough Medicines (CBM) Strikes Multi-Year Deal with UK Cell Therapy Powerhouse. News provided by.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $72M | 346 | -8% | N/A |
#2 | $195.4M | 352 | 43% | N/A |
#3 | $119.4M | 356 | 1% | N/A |
#4 | $69.8M | 376 | 4% | N/A |
#5 | $136.9M | 379 | 8% | N/A |